Skip to main content
. 2023 Jul 4;8(4):101593. doi: 10.1016/j.esmoop.2023.101593

Figure 2.

Figure 2

Reimbursement status of novel cancer medicine indications on 1 July 2022. Notes: The figure shows the proportion of indications with reimbursement (n = 124) on 1 July 2022 for indications that received EMA MA during the period 2011-2020. EMA, European Medicines Agency; MA, marketing authorization.